Premarket Roundup: CBRE Realty, Trimeris

By Associated Press March 14, 2008 Comments (0)

0 Recommendations

Among the premarket activity stories for Friday, March 14, from AP Financial News:

NEW YORK (AP) _ A potential sale of real estate investment trust CBRE Realty Finance Inc. is "far from certain," but is a possible scenario as the company has hired Goldman Sachs Group Inc. to review strategic alternatives, a research analyst said.

NEW YORK (AP) _ Analysts reduced profit estimates for biopharmaceutical company Trimeris Inc. Friday, pointing to decreasing sales of its HIV treatment Fuzeon.

NEW YORK (AP) _ Analysts said troubled bond insurer Security Capital Assurance Ltd.'s decision to stop writing new policies should free up about $75 million to $100 million of capital per quarter, and suspension of its quarterly dividend will make available an additional $40 million per year.

NEW YORK (AP) _ Slowing consumer spending and increased competition in southern U.S. markets will likely keep Hibbett Sports Inc. from hitting the high end of its profit guidance range, an analyst said Friday.

Comments (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment icon found on every comment.

Be the first one to comment on this article.

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Compare Brokers

DocumentId: 598549, ~/articles/articlehandler.aspx, 7/24/2008 1:35:35 AM,

Sign up for FREE Motley Fool site access!

Already registered? Login Here

It’s FREE! Enter your email address, and we’ll rush you to the article you're looking for right now.

Privacy / Legal Information

We will use your email address only to keep you informed about updates to our web site and about other products and services that we think might interest you. The Motley Fool respects your privacy. Please read our Privacy Statement